Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Spectral Medical ( (TSE:EDT) ) has issued an announcement.
Spectral Medical provided an update on its Tigris trial, a Phase 3 study evaluating the use of PMX in treating endotoxemia and septic shock. The company has enrolled 146 patients so far, aiming to reach 150 by the end of Q1 2025. The trial is significant for Spectral’s efforts to secure FDA approval in the U.S., enhancing its market position and potentially benefiting stakeholders involved in addressing septic shock, which affects approximately 330,000 patients in North America annually.
More about Spectral Medical
Spectral Medical Inc. is a late-stage theranostic company that focuses on advancing therapeutic options for sepsis and septic shock. The company’s primary product is Toraymyxin™ (PMX), a therapeutic hemoperfusion device designed to remove endotoxin from the bloodstream. Spectral Medical aims to obtain U.S. FDA approval for PMX, which is already approved in Japan and Europe and has been used on over 340,000 patients. The company is listed on the Toronto Stock Exchange under the symbol EDT.
YTD Price Performance: -0.27%
Average Trading Volume: 9,841
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $102.2M
See more insights into EDT stock on TipRanks’ Stock Analysis page.
